| 1 |
35168147 | Structural dynamics of the cooperative binding of small inhibitors in human cytochrome P450 2C9. | 2022 Jun |
1 |
| 2 |
33336382 | Metamizole is a Moderate Cytochrome P450 Inducer Via the Constitutive Androstane Receptor and a Weak Inhibitor of CYP1A2. | 2021 Jun |
1 |
| 3 |
31657866 | Pharmacokinetics and phenotyping properties of the Basel phenotyping cocktail combination capsule in healthy male adults. | 2020 Feb |
1 |
| 4 |
33147873 | Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Predict the Impact of CYP2C9 Genetic Polymorphisms, Co-Medication and Formulation on the Pharmacokinetics and Pharmacodynamics of Flurbiprofen. | 2020 Nov 2 |
2 |
| 5 |
27298492 | Evaluation of cytochrome P450 2C9 activity in normal, healthy, adult Western Indian population by both phenotyping and genotyping. | 2016 May-Jun |
2 |
| 6 |
25144335 | Effect of CYP2C9 genetic polymorphism on the metabolism of flurbiprofen in vitro. | 2015 |
2 |
| 7 |
25712887 | Effects of CYP2C9*1/*3 genotype on the pharmacokinetics of flurbiprofen in Korean subjects. | 2015 Jun |
7 |
| 8 |
25775139 | CYP2C9 genotype vs. metabolic phenotype for individual drug dosing--a correlation analysis using flurbiprofen as probe drug. | 2015 |
1 |
| 9 |
25875957 | Correction: CYP2C9 genotype vs. metabolic phenotype for individual drug dosing--a correlation analysis using flurbiprofen as probe drug. | 2015 |
1 |
| 10 |
24423593 | Simultaneous LC-MS/MS quantification of P-glycoprotein and cytochrome P450 probe substrates and their metabolites in DBS and plasma. | 2014 Jan |
1 |
| 11 |
22943633 | Effect of blueberry juice on clearance of buspirone and flurbiprofen in human volunteers. | 2013 Apr |
2 |
| 12 |
23737517 | Impact of severe hypothyroidism on cyclophosphamide disposition and routes of metabolism and transport in a patient with treatment-resistant lupus nephritis. | 2013 Jul-Aug |
1 |
| 13 |
22547083 | Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3. | 2012 Aug |
3 |
| 14 |
21223634 | Determination of pharmacokinetics of flurbiprofen in Pakistani population using modified HPLC method. | 2011 Feb |
2 |
| 15 |
20215413 | CYP2C9-CYP3A4 protein-protein interactions: role of the hydrophobic N terminus. | 2010 Jun |
1 |
| 16 |
19074529 | Mechanism of CYP2C9 inhibition by flavones and flavonols. | 2009 Mar |
1 |
| 17 |
19258521 | CYP2C9 amino acid residues influencing phenytoin turnover and metabolite regio- and stereochemistry. | 2009 Jun |
1 |
| 18 |
19448135 | CYP2D6-CYP2C9 protein-protein interactions and isoform-selective effects on substrate binding and catalysis. | 2009 Aug |
2 |
| 19 |
20167000 | New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part II. | 2009 Dec |
1 |
| 20 |
20167001 | New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. | 2009 Dec |
1 |
| 21 |
18237107 | Prediction of metabolism by cytochrome P450 2C9: alignment and docking studies of a validated database of substrates. | 2008 Feb 28 |
1 |
| 22 |
18378563 | Differential genotype dependent inhibition of CYP2C9 in humans. | 2008 Jul |
1 |
| 23 |
18922023 | Functional analysis of phenylalanine residues in the active site of cytochrome P450 2C9. | 2008 Nov 11 |
2 |
| 24 |
17054666 | Evaluation of flurbiprofen urinary ratios as in vivo indices for CYP2C9 activity. | 2007 Apr |
1 |
| 25 |
17960328 | Effective virtual screening protocol for CYP2C9 ligands using a screening site constructed from flurbiprofen and S-warfarin pockets. | 2007 Sep |
2 |
| 26 |
16928789 | Enzyme source effects on CYP2C9 kinetics and inhibition. | 2006 Nov |
1 |
| 27 |
16952492 | Validation of incorporating flurbiprofen into the Pittsburgh cocktail. | 2006 Sep |
1 |
| 28 |
15955872 | CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant. | 2005 Sep |
1 |
| 29 |
16118328 | Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? | 2005 Nov |
1 |
| 30 |
15130760 | Differential activation of CYP2C9 variants by dapsone. | 2004 May 15 |
5 |
| 31 |
15170358 | Effector-mediated alteration of substrate orientation in cytochrome P450 2C9. | 2004 Jun 8 |
7 |
| 32 |
15181000 | The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution. | 2004 Aug 20 |
1 |
| 33 |
12559973 | Activation of cytochrome P450 2C9-mediated metabolism: mechanistic evidence in support of kinetic observations. | 2003 Feb 1 |
2 |
| 34 |
12698304 | Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes. | 2003 Apr |
10 |
| 35 |
11901091 | Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles. | 2002 Apr |
4 |
| 36 |
11408370 | Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model. | 2001 Jul |
1 |
| 37 |
11457649 | Minimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsone. | 2001 Aug |
3 |
| 38 |
11129071 | Sensitive and specific high-performance liquid chromatographic assay for 4'-hydroxyflurbiprofen and flurbiprofen in human urine and plasma. | 2000 Nov 10 |
1 |
| 39 |
9521735 | Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. | 1998 Mar 24 |
1 |
| 40 |
9698079 | Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. | 1998 Jul 15 |
1 |
| 41 |
8937439 | Studies of flurbiprofen 4'-hydroxylation. Additional evidence suggesting the sole involvement of cytochrome P450 2C9. | 1996 Oct 25 |
2 |